Latest News - Amgen
Top Corporates Hub
Amgen
Former Highflier Argenx Plummets On A Surprise Setback In Sjogren's
08.10.2026 13:40
Argenx unexpectedly scrapped a study of its drug, Vyvgart, in patients with Sjogren's disease on Thursday. The stock plummeted in response.
Adlai Nortye Group: Only For The Risk-Tolerant After A Massive Rally
08.10.2026 11:45
Adlai Nortye Group has surged ~1,600% since Dec. 2025, fueled by private placements and preclinical data for its pan-RAS[ON] inhibitor AN9025. Learn more about ANL stock here.
Cantor Fitzgerald Maintains Neutral on Amgen, Raises Price Target to $440
08.10.2026 06:41
Cantor Fitzgerald analyst Carter Gould maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $400 to $440.
Amgen (AMGN) Backs $30 Million Series A Round In AI Genetic Testing
07.10.2026 13:07
Amgen (NasdaqGS:AMGN) took part in Arboretum LifeSciences' US$30 million Series A funding round focused on precision medicine. Arboretum LifeSciences plans to apply AI-driven genetic testing and molecular data tools to support more targeted healthcare decisions. The collaboration gives Amgen access to next-generation molecular information that may inform genomically targeted clinical trial design. There is more to Amgen's outlook than its Arboretum LifeSciences Series A funding participation...
Morgan Stanley Maintains Equal-Weight on Amgen, Lowers Price Target to $359
07.10.2026 10:22
Morgan Stanley analyst Terence Flynn maintains Amgen (NASDAQ:AMGN) with a Equal-Weight and lowers the price target from $362 to $359.
Has Eli Lilly Stock Peaked?
05.10.2026 14:19
One thing stands out at Eli Lilly (LLY): how many prescriptions are written for Zepbound and Mounjaro, which may be what buyers are betting on. You may think of them as high-priced drugs, but their U.S. prices are now falling. Yet the stock costs 38.2 times earnings, against 21.5 for the S&P 500. That is the tension. So, how much are the two drugs actually selling.
2 Profitable Stocks with Exciting Potential and 1 We Find Risky
01.10.2026 08:29
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
29.09.2026 01:27
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]
Amgen (AMGN) Has a New Growth Opportunity. But How Much Is It Really Worth?
29.09.2026 01:27
On September 22, Amgen Inc. (NASDAQ:AMGN) announced positive topline Phase 3 results for dazodalibep in systemic Sjögren’s disease. The trial met its primary endpoint, demonstrating statistically significant and clinically meaningful improvements in systemic disease activity. Following the announcement, Citi reaffirmed a Neutral rating and $405 price target on Amgen. While Citi noted that the results […]
Amgen (AMGN), What Is Behind The Fresh Attention?
29.09.2026 00:08
Amgen (AMGN) just reported positive topline data from its Phase 3 OASIZ 301 trial of dazodalibep in Sjögren's disease, an update that puts fresh attention on the stock's autoimmune pipeline potential. Set against that clinical update, Amgen’s share price has climbed 15.5% over the past 90 days and 27.6% year to date, while the 1-year total shareholder return of 56.9% and 5-year total shareholder return of 131.0% point to strong longer term momentum building around the story. Spot emerging...
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
24.09.2026 01:14
Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
24.09.2026 01:14
Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
23.09.2026 14:38
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results
23.09.2026 12:35
Key Stats for Amgen StockPrice change for Amgen stock in last 1 year: 43%$AMGN Stock Price as of Sep. 22: $41052-Week High: $447$AMGN Stock Price Target: $388What Happened?Amgen (AMGN) stock rose after the company shared positive Phase 3 trial results.
Capitalize on the PEGylated Proteins Revenue Shift: Benchmark Amgen, Roche, Merck KGaA, Pfizer and Novo Nordisk to Secure Competitive ROI Through the Forecast Period
22.09.2026 08:28
Site-specific PEGylation is enabling safer, longer-acting biologics, while demand in chronic disease, targeted therapies and biosimilars creates opportunities for services and reagents.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "PEGylated Proteins - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for PEGylated Proteins was estimated at US$2.0 Billion in 2025 and is projected to reach US$4.1 Billion by 2032, growing at a CAGR of 10.6% from 2
Morgan Stanley flags Amgen's edge after heart-drug rival stumbles
22.09.2026 03:07
A private meeting with Amgen management left Morgan Stanley with a very different read than the broader market’s.
Veeva Expands Amgen Partnership With Global Vault CRM Rollout Plan
21.09.2026 17:04
VEEV expands its decade-long Amgen partnership with a global Vault CRM rollout, reinforcing enterprise adoption and commercial subscription growth.
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
21.09.2026 16:03
Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
Amgen (AMGN) Stock Sees Modest Fair Value Lift As Analysts Weigh Pipeline Risks
19.09.2026 02:09
Amgen’s updated analyst model now points to a fair value price target of US$388.03, compared with the prior US$371.93. This provides a slightly higher anchor for how the stock is being valued today. This shift comes as recent research highlights a split view, with some analysts focusing on strong commercial execution and others stressing that questions around patents and the pipeline may already be reflected in the share price. As you read on, you will see how to interpret these moving...
Amgen Highlights MariTide, IMDELLTRA Pipeline Progress and Growth Priorities
16.09.2026 05:02
Amgen (NASDAQ:AMGN) outlined its growth priorities, late-stage pipeline progress and capital-allocation framework during a Morgan Stanley conference, as newly appointed Chief Financial Officer Thomas Dittrich emphasized execution, financial discipline and cash-on-cash returns. Dittrich, who previou